Pioglitazone (hydrochloride)

Pioglitazone (hydrochloride)

• CAS Number: 112529-15-4
• UNSPSC Description: Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
• Target Antigen: Ferroptosis; PPAR
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Cancer; Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/pioglitazone-hydrochloride.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CCC1=CN=C(CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2)C=C1.Cl
• Molecular Weight: 392.90
• References & Citations: [1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve|[2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.|[3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.|[4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33.Inflammation. 2020 Apr;43(2):568-578.|Int J Oncol. 2018 Aug;53(2):551-566.|J Diabetes Res. 2019 Feb 3;2019:5245063.|Mol Med Rep. 2024 Nov;30(5):209.|Mol Med Rep. 2019 Jan;19(1):400-406.|Acta Pharmacol Sin. 2021 Jan;42(1):160-170.|Adv Sci (Weinh). 2024 Oct 7:e2401931.|Am J Physiol Heart Circ Physiol. 2021 Apr 9.|Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151.|Biochem Eng J. 2021, 108104.|BMC Complement Med Ther. 2022 Jul 1;22(1):176.|Br J Pharmacol. 2021 Jun;178(11):2305-2323.|Cancer Res. 2022 Apr 15;82(8):1503-1517.|Cell Metab. 2021 Mar 2;33(3):581-597.e9.|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.|Food Chem Toxicol. 2021 Apr 6;112183.|Gut Microbes. 2022, 14(1): 2139978.|Heliyon. 2023 Apr 1.|Immunology. 2023 Jan 28.|Immunopharmacol Immunotoxicol. 2021 Aug 27;1-9.|J Adv Res. 2024 Sep 29:S2090-1232(24)00427-2.|J Steroid Biochem Mol Biol. 2023 Feb 1;229:106265.|Med Sci Monit. 2019 Nov 13;25:8544-8553.|Nutr Metab (Lond). 2019 Mar 5;16:17. |Oxid Med Cell Longev. 2022.|Res Sq. 2024 Jul 12.|Research Square Preprint. 2021 Mar.|SSRN. 2023 May 30.|Tunku Abdul Rahman University. 2024 Mar 11.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched